BACKGROUND: We evaluated the simultaneous resection of colorectal malignancies and synchronous liver metastases. METHODS: Between June 1982 and June 2006, a total of 752 patients underwent resection of colorectal hepatic metastases. In all, 185 (25%) of them underwent simultaneous resection of the hepatic lesions and the corresponding primary tumors. RESULTS: The median hospital stay was 8 days (range 4-24 days), with a median operating time of 4 h (range 2-8 h). Altogether, 62 (33.5%) patients required intraoperative transfusion of packed red blood cells (median 2.1 IU, range 1-5 IU), and 25 (13.5%) were given frozen fresh plasma (median 2.1 IU, range 1-4 IU). The morbidity rate was 20.5%. There were two postoperative deaths (mortality rate 1.08%) within 30 days of the surgical intervention. Major hepatectomy was associated with greater morbidity (37.2% vs. 16.2%, P < 0.01) and mortality (4.7% vs. 0%, P < 0.05) rates. For the overall survivals (OS) at 3 and 5 years were 60.1% (52.3-67.85%) and 36.1% (27.4-44.8%), respectively. Disease-free survivals (DFS) at 3 and 5 years were 37.7% (30.2-45.3%) and 26.5% (18.7-34.3%), respectively. Transfusion of blood products, CEA level > or = 200 ng/dl, and N2 node status were found to be prognostic factors by univariate analysis. CEA level > or = 200 ng/dl and N2 node status achieved prognostic significance by multivariate analysis. CONCLUSIONS: The simultaneous resection of colorectal malignancies and synchronous liver metastases is safe, avoids an additional intervention, can be performed with low morbidity and mortality, and is associated with good oncologic outcomes. Node stage N2 and CEA level > or = 200 ng/dl should be given special consideration when selecting patients.
BACKGROUND: We evaluated the simultaneous resection of colorectal malignancies and synchronous liver metastases. METHODS: Between June 1982 and June 2006, a total of 752 patients underwent resection of colorectal hepatic metastases. In all, 185 (25%) of them underwent simultaneous resection of the hepatic lesions and the corresponding primary tumors. RESULTS: The median hospital stay was 8 days (range 4-24 days), with a median operating time of 4 h (range 2-8 h). Altogether, 62 (33.5%) patients required intraoperative transfusion of packed red blood cells (median 2.1 IU, range 1-5 IU), and 25 (13.5%) were given frozen fresh plasma (median 2.1 IU, range 1-4 IU). The morbidity rate was 20.5%. There were two postoperative deaths (mortality rate 1.08%) within 30 days of the surgical intervention. Major hepatectomy was associated with greater morbidity (37.2% vs. 16.2%, P < 0.01) and mortality (4.7% vs. 0%, P < 0.05) rates. For the overall survivals (OS) at 3 and 5 years were 60.1% (52.3-67.85%) and 36.1% (27.4-44.8%), respectively. Disease-free survivals (DFS) at 3 and 5 years were 37.7% (30.2-45.3%) and 26.5% (18.7-34.3%), respectively. Transfusion of blood products, CEA level > or = 200 ng/dl, and N2 node status were found to be prognostic factors by univariate analysis. CEA level > or = 200 ng/dl and N2 node status achieved prognostic significance by multivariate analysis. CONCLUSIONS: The simultaneous resection of colorectal malignancies and synchronous liver metastases is safe, avoids an additional intervention, can be performed with low morbidity and mortality, and is associated with good oncologic outcomes. Node stage N2 and CEA level > or = 200 ng/dl should be given special consideration when selecting patients.
Authors: S Giacchetti; B Perpoint; R Zidani; N Le Bail; R Faggiuolo; C Focan; P Chollet; J F Llory; Y Letourneau; B Coudert; F Bertheaut-Cvitkovic; D Larregain-Fournier; A Le Rol; S Walter; R Adam; J L Misset; F Lévi Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Eduardo de Santibañes; Fernando Bonadeo Lassalle; Lucas McCormack; Juan Pekolj; Guillermo Ojea Quintana; Carlos Vaccaro; Mario Benati Journal: J Am Coll Surg Date: 2002-08 Impact factor: 6.113
Authors: Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2004 Jan-Feb Impact factor: 508.702
Authors: Robert Martin; Philip Paty; Yuman Fong; Andrew Grace; Alfred Cohen; Ronald DeMatteo; William Jarnagin; Leslie Blumgart Journal: J Am Coll Surg Date: 2003-08 Impact factor: 6.113
Authors: Srinevas K Reddy; Andrew S Barbas; Ryan S Turley; Jennifer L Steel; Allan Tsung; J Wallis Marsh; David A Geller; Bryan M Clary Journal: HPB (Oxford) Date: 2011-07 Impact factor: 3.647
Authors: Stefano Ferretti; Hadrien Tranchart; Joseph F Buell; Constantino Eretta; Alberto Patriti; Marcello Giuseppe Spampinato; Jung Wook Huh; Luca Vigano; Ho Seong Han; Giuseppe Maria Ettorre; Elio Jovine; Thomas Clark Gamblin; Giulio Belli; Go Wakabayashi; Brice Gayet; Ibrahim Dagher Journal: World J Surg Date: 2015-08 Impact factor: 3.352
Authors: Martin de Santibañes; Agustin Dietrich; Virginia Cano Busnelli; Juan Pekolj; Guillermo Ojea Quintana; Eduardo de Santibañes Journal: Updates Surg Date: 2015-02-17
Authors: Osama H Hamed; Neil H Bhayani; Gail Ortenzi; Jussuf T Kaifi; Eric T Kimchi; Kevin F Staveley-O'Carroll; Niraj J Gusani Journal: HPB (Oxford) Date: 2012-12-27 Impact factor: 3.647
Authors: Robert Öllinger; Andre L Mihaljevic; Christoph Schuhmacher; Hüseyin Bektas; Florian Vondran; Moritz Kleine; Mauricio Sainz-Barriga; Sascha Weiss; Phillip Knebel; Johann Pratschke; Roberto I Troisi Journal: HPB (Oxford) Date: 2012-12-27 Impact factor: 3.647